David A. Weber
Director/Board Member at Oculis SA
Profile
David A.
Weber currently works at Oculis SA, as Non-Executive Director from 2018.
Dr. Weber also formerly worked at MacuSight, Inc., as President & Chief Executive Officer, Oculex Pharmaceuticals, Inc., as Chief Executive Officer & Executive Vice President, On Demand Therapeutics, Inc., as Director from 2009 to 2014, Otonomy, Inc., as Director from 2022 to 2023, Procter & Gamble Co., as Senior Scientist-Healthcare Product Development, and Oral-B Laboratories, Inc., as Vice President-Research & Development.
Dr. Weber received his doctorate degree from Creighton University and undergraduate degree and graduate degree from Wichita State University.
David A. Weber active positions
Companies | Position | Start |
---|---|---|
Oculis SA
Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | Director/Board Member | 2018-09-18 |
Former positions of David A. Weber
Companies | Position | End |
---|---|---|
OTONOMY | Chief Executive Officer | 2022-12-14 |
On Demand Therapeutics, Inc.
On Demand Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology On Demand Therapeutics, Inc. develops implantable devices to enable on demand release of drugs to the back of the eye. The firm also develops small injectable ophthalmic implants containing multiple laser-activated reservoirs designed for the treatment of sight-threatening diseases of the retina. The company was founded on September 22, 2008 and is headquartered in Menlo Park, CA. | Director/Board Member | 2014-06-30 |
MacuSight, Inc.
MacuSight, Inc. Pharmaceuticals: MajorHealth Technology MacuSight, Inc. develops and manufactures pharmaceuticals products. The firm engages in developing therapeutics for the treatment of severe ocular diseases and conditions. It offers sirolimus, a therapeutic for the treatment and prevention of wet age-related macular degeneration, as well as for the treatment of diabetic macular edema; and related compounds and other select therapeutics in the eye, as well as minimally-invasive ocular formulations. The company was founded in 2003 and is headquartered in Union City, CA. | Chief Executive Officer | - |
PROCTER & GAMBLE COMPANY | Corporate Officer/Principal | - |
Oculex Pharmaceuticals, Inc.
Oculex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Oculex Pharmaceuticals, Inc. manufactures and develops drugs. The company focuses on developing and manufacturing novel drug delivery systems that resolve the problems associated with treatment of inflammation following cataract surgery and diseases of the eye. It is located in Sunnyvale, CA. | Chief Executive Officer | - |
Training of David A. Weber
Creighton University | Doctorate Degree |
Wichita State University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
PROCTER & GAMBLE COMPANY | Consumer Non-Durables |
Private companies | 6 |
---|---|
MacuSight, Inc.
MacuSight, Inc. Pharmaceuticals: MajorHealth Technology MacuSight, Inc. develops and manufactures pharmaceuticals products. The firm engages in developing therapeutics for the treatment of severe ocular diseases and conditions. It offers sirolimus, a therapeutic for the treatment and prevention of wet age-related macular degeneration, as well as for the treatment of diabetic macular edema; and related compounds and other select therapeutics in the eye, as well as minimally-invasive ocular formulations. The company was founded in 2003 and is headquartered in Union City, CA. | Health Technology |
On Demand Therapeutics, Inc.
On Demand Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology On Demand Therapeutics, Inc. develops implantable devices to enable on demand release of drugs to the back of the eye. The firm also develops small injectable ophthalmic implants containing multiple laser-activated reservoirs designed for the treatment of sight-threatening diseases of the retina. The company was founded on September 22, 2008 and is headquartered in Menlo Park, CA. | Health Technology |
Oculex Pharmaceuticals, Inc.
Oculex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Oculex Pharmaceuticals, Inc. manufactures and develops drugs. The company focuses on developing and manufacturing novel drug delivery systems that resolve the problems associated with treatment of inflammation following cataract surgery and diseases of the eye. It is located in Sunnyvale, CA. | Health Technology |
Oral-B Laboratories, Inc.
Oral-B Laboratories, Inc. Medical SpecialtiesHealth Technology Oral-B Laboratories, Inc. manufactures oral hygiene products, such as power and manual toothbrushes, floss, irrigation products, toothpaste and mouth rinse. Its products are sold directly to dental offices, through retail outlets. The company was founded in 1950 and is located in Boston, MA. | Health Technology |
Otonomy, Inc.
Otonomy, Inc. BiotechnologyHealth Technology Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm’s product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA. | Health Technology |
Oculis SA
Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | Commercial Services |
- Stock Market
- Insiders
- David A. Weber